Evaluation	B:C0220825
of	O
the	O
Financial	O
and	O
Health	O
Burden	O
of	O
Infants	O
at	O
Risk	O
for	O
Respiratory	O
Syncytial	I:C0035236
Virus	I:C0035236
.	O

Evaluation	O
of	O
the	O
Financial	O
and	O
Health	O
Burden	O
of	O
Infants	O
at	O
Risk	O
for	O
Respiratory	B:C0035236
Syncytial	I:C0035236
Virus	I:C0035236
.	O

Respiratory	B:C0035236
syncytial	I:C0035236
virus	I:C0035236
(	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
)	O
is	O
the	O
leading	O
viral	O
cause	I:C0007465
of	I:C0007465
death	I:C0007465
in	O
infants	O
younger	O
than	O
1	O
year	O
.	O

Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
(	O
Respiratory	B:C0035236
syncytial	I:C0035236
virus	I:C0035236
)	O
is	O
the	O
leading	O
viral	O
cause	I:C0007465
of	I:C0007465
death	I:C0007465
in	O
infants	O
younger	O
than	O
1	O
year	O
.	O

Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
(	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
)	O
is	O
the	O
leading	O
viral	B:C0007465
cause	I:C0007465
of	I:C0007465
death	I:C0007465
in	O
infants	O
younger	O
than	O
1	O
year	O
.	O

In	O
July	O
2014	O
,	O
the	O
American	B:C1708333
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
(	I:C1708333
AAP	I:C1708333
)	I:C1708333
Committee	I:C1708333
on	O
Infectious	O
Diseases	I:C0009450
concluded	O
that	O
the	O
"	O
limited	O
clinical	O
benefit	O
"	O
for	O
infants	O
born	O
at	O
more	O
than	O
29	O
weeks	O
'	I:C1135241
gestation	I:C1135241
,	I:C1135241
together	O
with	O
the	O
associated	O
high	O
cost	O
of	O
the	O
immunoprophylaxis	O
,	O
no	O
longer	O
supported	O
the	O
routine	O
use	O
of	O
palivizumab	O
(	O
Synagis	O
)	O
.	O

In	O
July	O
2014	O
,	O
the	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
(	I:C1708333
AAP	I:C1708333
)	I:C1708333
Committee	I:C1708333
on	O
Infectious	B:C0009450
Diseases	I:C0009450
concluded	O
that	O
the	O
"	O
limited	O
clinical	O
benefit	O
"	O
for	O
infants	O
born	O
at	O
more	O
than	O
29	O
weeks	O
'	I:C1135241
gestation	I:C1135241
,	I:C1135241
together	O
with	O
the	O
associated	O
high	O
cost	O
of	O
the	O
immunoprophylaxis	O
,	O
no	O
longer	O
supported	O
the	O
routine	O
use	O
of	O
palivizumab	O
(	O
Synagis	O
)	O
.	O

In	O
July	O
2014	O
,	O
the	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
(	I:C1708333
AAP	I:C1708333
)	I:C1708333
Committee	I:C1708333
on	O
Infectious	O
Diseases	I:C0009450
concluded	O
that	O
the	O
"	O
limited	O
clinical	O
benefit	O
"	O
for	O
infants	O
born	O
at	O
more	O
than	O
29	O
weeks	B:C1135241
'	I:C1135241
gestation	I:C1135241
,	I:C1135241
together	O
with	O
the	O
associated	O
high	O
cost	O
of	O
the	O
immunoprophylaxis	O
,	O
no	O
longer	O
supported	O
the	O
routine	O
use	O
of	O
palivizumab	O
(	O
Synagis	O
)	O
.	O

In	O
July	O
2014	O
,	O
the	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
(	I:C1708333
AAP	I:C1708333
)	I:C1708333
Committee	I:C1708333
on	O
Infectious	O
Diseases	I:C0009450
concluded	O
that	O
the	O
"	O
limited	O
clinical	O
benefit	O
"	O
for	O
infants	O
born	O
at	O
more	O
than	O
29	O
weeks	O
'	I:C1135241
gestation	I:C1135241
,	I:C1135241
together	O
with	O
the	O
associated	O
high	O
cost	O
of	O
the	O
immunoprophylaxis	B:C0020971
,	O
no	O
longer	O
supported	O
the	O
routine	O
use	O
of	O
palivizumab	O
(	O
Synagis	O
)	O
.	O

In	O
July	O
2014	O
,	O
the	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
(	I:C1708333
AAP	I:C1708333
)	I:C1708333
Committee	I:C1708333
on	O
Infectious	O
Diseases	I:C0009450
concluded	O
that	O
the	O
"	O
limited	O
clinical	O
benefit	O
"	O
for	O
infants	O
born	O
at	O
more	O
than	O
29	O
weeks	O
'	I:C1135241
gestation	I:C1135241
,	I:C1135241
together	O
with	O
the	O
associated	O
high	O
cost	O
of	O
the	O
immunoprophylaxis	O
,	O
no	O
longer	O
supported	O
the	O
routine	O
use	O
of	O
palivizumab	B:C0672596
(	O
Synagis	O
)	O
.	O

In	O
July	O
2014	O
,	O
the	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
(	I:C1708333
AAP	I:C1708333
)	I:C1708333
Committee	I:C1708333
on	O
Infectious	O
Diseases	I:C0009450
concluded	O
that	O
the	O
"	O
limited	O
clinical	O
benefit	O
"	O
for	O
infants	O
born	O
at	O
more	O
than	O
29	O
weeks	O
'	I:C1135241
gestation	I:C1135241
,	I:C1135241
together	O
with	O
the	O
associated	O
high	O
cost	O
of	O
the	O
immunoprophylaxis	O
,	O
no	O
longer	O
supported	O
the	O
routine	O
use	O
of	O
palivizumab	O
(	O
Synagis	B:C0723567
)	O
.	O

To	O
evaluate	B:C0220825
the	O
impact	O
of	O
the	O
newly	O
adopted	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
palivizumab	O
prophylaxis	O
administration	I:C0199176
on	O
health	O
and	O
subsequent	O
hospital	O
costs	O
of	O
infants	O
born	O
between	O
29	O
and	O
less	O
than	O
32	O
weeks	O
'	I:C1135241
gestation	I:C1135241
.	O

To	O
evaluate	O
the	O
impact	O
of	O
the	O
newly	O
adopted	O
American	B:C1708333
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
palivizumab	O
prophylaxis	O
administration	I:C0199176
on	O
health	O
and	O
subsequent	O
hospital	O
costs	O
of	O
infants	O
born	O
between	O
29	O
and	O
less	O
than	O
32	O
weeks	O
'	I:C1135241
gestation	I:C1135241
.	O

To	O
evaluate	O
the	O
impact	O
of	O
the	O
newly	O
adopted	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
palivizumab	B:C0672596
prophylaxis	O
administration	I:C0199176
on	O
health	O
and	O
subsequent	O
hospital	O
costs	O
of	O
infants	O
born	O
between	O
29	O
and	O
less	O
than	O
32	O
weeks	O
'	I:C1135241
gestation	I:C1135241
.	O

To	O
evaluate	O
the	O
impact	O
of	O
the	O
newly	O
adopted	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
palivizumab	O
prophylaxis	B:C0199176
administration	I:C0199176
on	O
health	O
and	O
subsequent	O
hospital	O
costs	O
of	O
infants	O
born	O
between	O
29	O
and	O
less	O
than	O
32	O
weeks	O
'	I:C1135241
gestation	I:C1135241
.	O

To	O
evaluate	O
the	O
impact	O
of	O
the	O
newly	O
adopted	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
palivizumab	O
prophylaxis	O
administration	I:C0199176
on	O
health	O
and	O
subsequent	O
hospital	O
costs	O
of	O
infants	O
born	O
between	O
29	O
and	O
less	O
than	O
32	O
weeks	B:C1135241
'	I:C1135241
gestation	I:C1135241
.	O

A	O
retrospective	O
cohort	B:C0086027
analysis	I:C0086027
from	O
a	O
single	O
institution	O
across	O
the	O
duration	O
of	O
the	O
study	O
comparing	O
the	O
clinical	O
and	O
financial	O
outcomes	O
of	O
infants	O
(	O
aged	O
<	O
32	O
weeks	O
)	O
treated	O
under	O
the	O
2009	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
guidelines	O
(	O
PRE	O
)	O
and	O
infants	O
(	O
aged	O
>	O
29	O
weeks	O
)	O
managed	O
after	O
the	O
2014	O
AAP	O
guidelines	I:C0282574
(	O
POST	O
)	O
took	O
effect	O
.	O

A	O
retrospective	O
cohort	O
analysis	I:C0086027
from	O
a	O
single	O
institution	O
across	O
the	O
duration	O
of	O
the	O
study	B:C2603343
comparing	O
the	O
clinical	O
and	O
financial	O
outcomes	O
of	O
infants	O
(	O
aged	O
<	O
32	O
weeks	O
)	O
treated	O
under	O
the	O
2009	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
guidelines	O
(	O
PRE	O
)	O
and	O
infants	O
(	O
aged	O
>	O
29	O
weeks	O
)	O
managed	O
after	O
the	O
2014	O
AAP	O
guidelines	I:C0282574
(	O
POST	O
)	O
took	O
effect	O
.	O

A	O
retrospective	O
cohort	O
analysis	I:C0086027
from	O
a	O
single	O
institution	O
across	O
the	O
duration	O
of	O
the	O
study	O
comparing	O
the	O
clinical	O
and	O
financial	O
outcomes	O
of	O
infants	O
(	O
aged	O
<	O
32	O
weeks	O
)	O
treated	B:C0332154
under	O
the	O
2009	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
guidelines	O
(	O
PRE	O
)	O
and	O
infants	O
(	O
aged	O
>	O
29	O
weeks	O
)	O
managed	O
after	O
the	O
2014	O
AAP	O
guidelines	I:C0282574
(	O
POST	O
)	O
took	O
effect	O
.	O

A	O
retrospective	O
cohort	O
analysis	I:C0086027
from	O
a	O
single	O
institution	O
across	O
the	O
duration	O
of	O
the	O
study	O
comparing	O
the	O
clinical	O
and	O
financial	O
outcomes	O
of	O
infants	O
(	O
aged	O
<	O
32	O
weeks	O
)	O
treated	O
under	O
the	O
2009	O
American	B:C1708333
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
guidelines	O
(	O
PRE	O
)	O
and	O
infants	O
(	O
aged	O
>	O
29	O
weeks	O
)	O
managed	O
after	O
the	O
2014	O
AAP	O
guidelines	I:C0282574
(	O
POST	O
)	O
took	O
effect	O
.	O

A	O
retrospective	O
cohort	O
analysis	I:C0086027
from	O
a	O
single	O
institution	O
across	O
the	O
duration	O
of	O
the	O
study	O
comparing	O
the	O
clinical	O
and	O
financial	O
outcomes	O
of	O
infants	O
(	O
aged	O
<	O
32	O
weeks	O
)	O
treated	O
under	O
the	O
2009	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
guidelines	B:C0162791
(	O
PRE	O
)	O
and	O
infants	O
(	O
aged	O
>	O
29	O
weeks	O
)	O
managed	O
after	O
the	O
2014	O
AAP	O
guidelines	I:C0282574
(	O
POST	O
)	O
took	O
effect	O
.	O

A	O
retrospective	O
cohort	O
analysis	I:C0086027
from	O
a	O
single	O
institution	O
across	O
the	O
duration	O
of	O
the	O
study	O
comparing	O
the	O
clinical	O
and	O
financial	O
outcomes	O
of	O
infants	O
(	O
aged	O
<	O
32	O
weeks	O
)	O
treated	O
under	O
the	O
2009	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
guidelines	O
(	O
PRE	O
)	O
and	O
infants	O
(	O
aged	O
>	O
29	O
weeks	O
)	O
managed	O
after	O
the	O
2014	O
AAP	B:C0282574
guidelines	I:C0282574
(	O
POST	O
)	O
took	O
effect	O
.	O

RSV	O
-	O
positive	O
admissions	B:C0184666
were	O
greater	O
in	O
the	O
POST	O
cohort	I:C0599755
versus	O
the	O
PRE	O
cohor	I:C0599755
t	O
(	O
P	O
=	O
.04	O
)	O
.	O

RSV	O
-	O
positive	O
admissions	O
were	O
greater	O
in	O
the	O
POST	B:C0599755
cohort	I:C0599755
versus	O
the	O
PRE	O
cohor	I:C0599755
t	O
(	O
P	O
=	O
.04	O
)	O
.	O

RSV	O
-	O
positive	O
admissions	O
were	O
greater	O
in	O
the	O
POST	O
cohort	I:C0599755
versus	O
the	O
PRE	B:C0599755
cohor	I:C0599755
t	O
(	O
P	O
=	O
.04	O
)	O
.	O

There	O
were	O
no	B:C1513916
readmission	O
deaths	O
due	O
to	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
infection	O
in	O
either	O
cohort	O
.	O

There	O
were	O
no	O
readmission	B:C0184666
deaths	O
due	O
to	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
infection	O
in	O
either	O
cohort	O
.	O

There	O
were	O
no	O
readmission	O
deaths	B:C0011065
due	O
to	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
infection	O
in	O
either	O
cohort	O
.	O

There	O
were	O
no	O
readmission	O
deaths	O
due	O
to	O
Respiratory	B:C0035236
syncytial	I:C0035236
virus	I:C0035236
infection	O
in	O
either	O
cohort	O
.	O

There	O
were	O
no	O
readmission	O
deaths	O
due	O
to	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
infection	B:C3714514
in	O
either	O
cohort	O
.	O

There	O
were	O
no	O
readmission	O
deaths	O
due	O
to	O
Respiratory	O
syncytial	I:C0035236
virus	I:C0035236
infection	O
in	O
either	O
cohort	B:C0599755
.	O

The	O
number	O
needed	O
to	O
treat	O
to	O
avoid	O
a	O
single	O
RSV	O
-	O
positive	O
hospitalization	B:C0019993
was	O
20	O
infants	O
at	O
an	O
estimated	O
palivizumab	O
cost	O
of	O
$	O
90,000	O
to	O
avoid	O
an	O
estimated	O
hospital	O
cost	O
of	O
$	O
29,000	O
.	O

The	O
number	O
needed	O
to	O
treat	O
to	O
avoid	O
a	O
single	O
RSV	O
-	O
positive	O
hospitalization	O
was	O
20	O
infants	O
at	O
an	O
estimated	O
palivizumab	B:C0672596
cost	O
of	O
$	O
90,000	O
to	O
avoid	O
an	O
estimated	O
hospital	O
cost	O
of	O
$	O
29,000	O
.	O

Assessment	B:C0220825
of	O
individual	O
risk	O
factors	I:C0035648
and	O
their	O
ability	O
to	O
predict	O
severe	O
RSV	O
risk	O
/	O
disease	O
,	O
thus	O
,	O
would	O
allow	O
providers	O
greater	O
flexibility	O
in	O
determining	O
need	O
for	O
prophylaxis	O
therapy	I:C0199176
.	O

Assessment	O
of	O
individual	O
risk	B:C0035648
factors	I:C0035648
and	O
their	O
ability	O
to	O
predict	O
severe	O
RSV	O
risk	O
/	O
disease	O
,	O
thus	O
,	O
would	O
allow	O
providers	O
greater	O
flexibility	O
in	O
determining	O
need	O
for	O
prophylaxis	O
therapy	I:C0199176
.	O

Assessment	O
of	O
individual	O
risk	O
factors	I:C0035648
and	O
their	O
ability	O
to	O
predict	O
severe	O
RSV	O
risk	O
/	O
disease	B:C0012634
,	O
thus	O
,	O
would	O
allow	O
providers	O
greater	O
flexibility	O
in	O
determining	O
need	O
for	O
prophylaxis	O
therapy	I:C0199176
.	O

Assessment	O
of	O
individual	O
risk	O
factors	I:C0035648
and	O
their	O
ability	O
to	O
predict	O
severe	O
RSV	O
risk	O
/	O
disease	O
,	O
thus	O
,	O
would	O
allow	O
providers	O
greater	O
flexibility	O
in	O
determining	O
need	O
for	O
prophylaxis	B:C0199176
therapy	I:C0199176
.	O

Longitudinal	B:C0220825
evaluation	I:C0220825
of	O
financial	O
and	O
clinical	O
outcomes	O
is	O
needed	O
to	O
determine	O
the	O
impact	O
of	O
the	O
2014	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
revised	O
regulatory	O
guidelines	I:C0162791
.	O

Longitudinal	O
evaluation	I:C0220825
of	O
financial	O
and	O
clinical	O
outcomes	O
is	O
needed	O
to	O
determine	O
the	O
impact	O
of	O
the	O
2014	O
American	B:C1708333
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
revised	O
regulatory	O
guidelines	I:C0162791
.	O

Longitudinal	O
evaluation	I:C0220825
of	O
financial	O
and	O
clinical	O
outcomes	O
is	O
needed	O
to	O
determine	O
the	O
impact	O
of	O
the	O
2014	O
American	O
Academy	I:C1708333
of	I:C1708333
Pediatrics	I:C1708333
revised	O
regulatory	B:C0162791
guidelines	I:C0162791
.	O

